Alexion joins the R&D reorganization gala, pruning a slate of projects and revving up new deals
Alexion CEO Ludwig Hantson is pulling the trigger on a pipeline reorganization, joining a mid-year gala of restructurings led by new CEOs at GlaxoSmithKline, Eli Lilly and Biogen.
In the revamp the biotech will now drop ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab), looking for buyers to pick these therapies up. And it is punting an ambitious effort on a range of preclinical pacts with Moderna, Blueprint and Arbutus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.